Vanguard Group Inc. Has $598.16 Million Stock Position in Doximity, Inc. (NASDAQ:DOCS)

Vanguard Group Inc. raised its holdings in Doximity, Inc. (NASDAQ:DOCS) by 4.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 11,203,569 shares of the company’s stock after purchasing an additional 485,102 shares during the quarter. Vanguard Group Inc. owned 6.00% of Doximity worth $598,159,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of DOCS. Global Retirement Partners LLC lifted its position in shares of Doximity by 468.1% during the 4th quarter. Global Retirement Partners LLC now owns 534 shares of the company’s stock worth $29,000 after buying an additional 440 shares during the last quarter. UMB Bank n.a. raised its stake in Doximity by 69.1% during the fourth quarter. UMB Bank n.a. now owns 575 shares of the company’s stock worth $31,000 after acquiring an additional 235 shares in the last quarter. Larson Financial Group LLC lifted its holdings in shares of Doximity by 49.4% in the fourth quarter. Larson Financial Group LLC now owns 756 shares of the company’s stock worth $40,000 after acquiring an additional 250 shares during the last quarter. Optimum Investment Advisors acquired a new stake in shares of Doximity in the 4th quarter valued at approximately $43,000. Finally, Morse Asset Management Inc bought a new stake in shares of Doximity during the 3rd quarter valued at approximately $46,000. Institutional investors own 87.19% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on DOCS. Piper Sandler upgraded shares of Doximity from a “neutral” rating to an “overweight” rating and raised their target price for the company from $31.00 to $78.00 in a research report on Friday, February 7th. Needham & Company LLC raised their price objective on Doximity from $65.00 to $82.00 and gave the company a “buy” rating in a report on Friday, February 7th. Wells Fargo & Company reaffirmed an “equal weight” rating on shares of Doximity in a report on Friday, February 7th. Mizuho lifted their price target on Doximity from $55.00 to $65.00 and gave the company a “neutral” rating in a research note on Monday, February 10th. Finally, KeyCorp lowered their price objective on Doximity from $70.00 to $65.00 and set an “overweight” rating for the company in a research note on Wednesday, January 8th. Eleven investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $64.22.

Insider Buying and Selling at Doximity

In other news, Director Timothy S. Cabral sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $57.62, for a total transaction of $1,152,400.00. Following the completion of the sale, the director now owns 6,360 shares of the company’s stock, valued at $366,463.20. This trade represents a 75.87 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders own 37.40% of the company’s stock.

Doximity Price Performance

Shares of NASDAQ:DOCS opened at $58.11 on Tuesday. The business’s 50-day moving average is $65.57 and its 200-day moving average is $54.69. Doximity, Inc. has a 1 year low of $22.96 and a 1 year high of $85.21. The company has a market capitalization of $10.85 billion, a price-to-earnings ratio of 58.11, a P/E/G ratio of 4.10 and a beta of 1.34.

Doximity Company Profile

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.